These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35695577)

  • 1. Mutation of
    Zhao X; Jin Y; Bai F; Cheng Z; Wu W; Pan X
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0042122. PubMed ID: 35695577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
    Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W
    Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Karlowsky JA; Kazmierczak KM; de Jonge BLM; Hackel MA; Sahm DF; Bradford PA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
    Le Terrier C; Nordmann P; Poirel L
    J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
    Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
    Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
    Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
    Davido B; Fellous L; Lawrence C; Maxime V; Rottman M; Dinh A
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630191
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
    Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
    Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
    Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
    Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
    Poirel L; Ortiz de la Rosa JM; Sadek M; Nordmann P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0003922. PubMed ID: 35315685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.
    Montaner M; Lopez-Argüello S; Oliver A; Moya B
    Microbiol Spectr; 2023 Feb; 11(1):e0303822. PubMed ID: 36475840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.
    Lahiri SD; Johnstone MR; Ross PL; McLaughlin RE; Olivier NB; Alm RA
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5704-13. PubMed ID: 25022578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.